Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline • Bladder • Bladder cancer • Currently approved therapeutic regimen • Stages of bladder cancer PART 05: Key clinical trials PART 06: Market landscape • Market size and forecast • Five forces analysis PART 07: Market segmentation by therapy • Intravesical therapy • Chemotherapy • Preservation therapy • Others PART 08: Geographical segmentation • Bladder cancer therapeutics market in Americas • Bladder cancer therapeutics market in EMEA • Bladder cancer therapeutics market in APAC PART 09: Decision framework PART 10: Drivers and challenges • Market drivers • Market challenges PART 11: Market trends • Growing influence of targeted biologics • Advent of novel pipeline • Emergence of effective diagnostic tools PART 12: Vendor landscape • Competitive landscape PART 13: Key vendor analysis • Bristol-Myers Squibb • Eli Lilly • F. Hoffman-La Roche • Pfizer • Other prominent vendors PART 14: Appendix • List of abbreviations List of Exhibits Exhibit 01: Approved therapeutics for the treatment of bladder cancer Exhibit 02: Stages of bladder cancer Exhibit 03: Pipeline landscape based on development phase 2016 Exhibit 04: Key clinical trials Exhibit 05: Snapshot of therapy-based pipeline in global bladder cancer market Exhibit 06: Market scenario for global bladder cancer therapeutics market 2016-2021 ($ million) Exhibit 07: Global bladder cancer therapeutics market revenue 2016-2021 ($ millions) Exhibit 08: Opportunity analysis of global bladder cancer therapeutics market Exhibit 09: Five forces analysis Exhibit 10: Segmentation of global bladder cancer therapeutics market by therapy 2016 Exhibit 11: Global bladder cancer therapeutics market segmentation based on therapy 2016 (%) Exhibit 12: Global bladder cancer therapeutics market for intravesical therapy 2016-2021 ($ millions) Exhibit 13: Global bladder cancer therapeutics market for chemotherapy 2016-2021 ($ millions) Exhibit 14: Global bladder cancer therapeutics market for preservation therapy 2016-2021 ($ millions) Exhibit 15: Segmentation of global bladder cancer therapeutics market based on geography 2016 and 2021 Exhibit 16: Global bladder cancer therapeutics market revenue by geography 2016-2021 ($ millions) Exhibit 17: Global bladder cancer therapeutics market share by geography 2016-2021 (%) Exhibit 18: Market scenario in Americas Exhibit 19: Bladder cancer therapeutics market in Americas 2016-2021 ($ millions) Exhibit 20: Market scenario in EMEA Exhibit 21: Bladder cancer therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 22: Market scenario in APAC Exhibit 23: Bladder cancer therapeutics market in APAC 2016-2021 ($ millions) Exhibit 24: Competitive structure analysis of global bladder cancer therapeutics market 2016 Exhibit 25: Bristol-Myers Squibb: Key highlights Exhibit 26: Bristol-Myers Squibb: Strength assessment Exhibit 27: Bristol-Myers Squibb: Strategy assessment Exhibit 28: Bristol-Myers Squibb: Opportunity assessment Exhibit 29: Eli Lilly: Key highlights Exhibit 30: Eli Lilly: Strength assessment Exhibit 31: Eli Lilly: Strategy assessment Exhibit 32: Eli Lilly: Opportunity assessment Exhibit 33: F. Hoffman-La Roche: Key highlights Exhibit 34: F. Hoffman-La Roche: Strength assessment Exhibit 35: F. Hoffman-La Roche: Strategy assessment Exhibit 36: F. Hoffman-La Roche: Opportunity assessment Exhibit 37: Pfizer: Key highlights Exhibit 38: Pfizer: Strength assessment Exhibit 39: Pfizer: Strategy assessment Exhibit 40: Pfizer: Opportunity assessment

Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Pfizer, Accord Healthcare, AstraZeneca, Bedford Lab, Merck, and Sanofi.